Table 1 The baseline characteristics
n = 107 | |
|---|---|
Male | 65 (60.7) |
Age, years | 63.4 (1.1) |
Positive for smoking history | 59 (55.1) |
(Current smoker) | 18 (16.8) |
(Ex-smoker) | 41 (38.3) |
Brinkman Index | 530.9 (79.0) |
History of occupational exposure positive | 48 (44.9) |
Lung function test | |
VC, ml | 2,544 (103.5) |
VC,% predicted | 80.2 (2.5) |
FEV1, ml | 2,012.2 (78.5) |
FEV1% | 77.8 (1.5) |
DLCO,% predicted | 69.0 (3.0) |
KL-6 in serum, U/ml | 1,173.7 (111.9) |
CT findings | |
Ground glass opacity or/and reticular shadow | 72 (67.2) |
Consolidation | 31 (29.0) |
Bronchiectasis | 42 (39.2) |
Honeycomb | 24 (22.4) |
Emphysema | 29 (27.1) |
Plaque | 7 (6.5) |
BALF | |
Total cell, ×105/ml | 6.6 (2.2) |
Macrophage,% | 68.4 (2.2) |
Lymphocyte,% | 15.4 (1.7) |
Eosinophil,% | 5.3 (0.9) |
Neutrophil,% | 11.5 (1.9) |
CD4/8 | 2.7 (0.3) |
Diagnosis of diffuse lung diseases | |
Asbestosis | 6 (5.6) |
IPF | 26 (24.2) |
IIPs other than IPF | 14 (13.1) |
CHP | 10 (9.3) |
CEP | 7 (6.5) |
CTD with diffuse lung diseases | 14 (13.1) |
Sarcoidosis | 15 (14.0) |
Other diffuse lung diseases | 15 (14.0) |